Uniqure turns the screw on Spark and Pfizer
After Earlier Dramatic Gene Therapy Collapse, uniQure’s Hemophilia B Therapy Showing Promise
Gene therapy: how much will it cost patients?
Gene therapy deal-making shows no signs of stopping
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. Over the weekend the company … Continue Reading uniQure, Bioverativ Unveil Positive Data for Hemophilia B and Hemophilia A Patients
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project (“HGP”), this precise and personal approach to medicine is an emerging discipline with enormous disruptive … Continue Reading Genomic Medicine: Catch The Gene Therapy Wave
Over 10,000 human diseases are caused by exactly one faulty gene. Gene therapy promises to fix each of them. Here’s a review of biotech’s progress. Biotech is arguably built on genetic … Continue Reading Reviewing Gene Therapy: How Close is Biotech to Genetic Cures?
Experts say hemophilia treatment is at a ‘precipice of a therapeutic revolution.’ From antibodies to gene therapy, here are some of the most innovative technologies in the field that might … Continue Reading How is Biotech Innovating to Treat Hemophilia? Let’s Review